Paper19088047
A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies.
Schimmer AD and 17 others. Clin Cancer Res, 2008. Cited by 154 papers, by iCite.
Cite this record
ConductScience Library. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Papers, record 19088047. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19088047
- Disease
- acute myeloid leukemia587 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies.
- PubMed
Connected records6
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Diseases6
- acute myeloid leukemiaOne of its trials lists the paper587 drugs, 2,158 trials
- myelodysplastic syndromeOne of its trials lists the paper421 drugs, 1,221 trials
- B-cell chronic lymphocytic leukemiaOne of its trials lists the paper345 drugs, 1,022 trials
- chronic myeloid leukemiaOne of its trials lists the paper179 drugs, 548 trials
- myelofibrosisOne of its trials lists the paper125 drugs, 210 trials
- aplastic anemiaOne of its trials lists the paper62 drugs, 147 trials
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Leukemia | Major topic |
| Proto-Oncogene Proteins c-bcl-2 | Major topic |
| Pyrroles | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Electrocardiography | |
| Female | |
| Humans | |
| Indoles | |
| Male | |
| Middle Aged |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P30CA016672 | NIH |
Source NIH RePORTER
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT00438178 | Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies | Results |
Source ClinicalTrials.gov
Cited by95
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 154 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41596764 | BCL-2 and BCL-xL in Cancer: Regulation, Function, and Therapeutic Targeting. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41596764 | PubMed |
| 39456607 | Insights into Metabolic Reprogramming in Tumor Evolution and Therapy. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39456607 | PubMed |
| 39060763 | Combination of BCL-2 inhibitors and immunotherapy: a promising therapeutic strategy for hematological malignancies. | Discov Oncol | 2024 | https://conductscience.org/library/papers/39060763 | PubMed |
| 37834104 | Design, Synthesis, and Potent Anticancer Activity of Novel Indole-Based Bcl-2 Inhibitors. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37834104 | PubMed |
| 37759469 | Obatoclax Rescues FUS-ALS Phenotypes in iPSC-Derived Neurons by Inducing Autophagy. | Cells | 2023 | https://conductscience.org/library/papers/37759469 | PubMed |
| 37744063 | Advancement of regulating cellular signaling pathways in NSCLC target therapy via nanodrug. | Front Chem | 2023 | https://conductscience.org/library/papers/37744063 | PubMed |
| 37168341 | The signature of immune-subtype specific driving transcription factors suggest potential drugs for refractory glioblastoma. | Am J Cancer Res | 2023 | https://conductscience.org/library/papers/37168341 | PubMed |
| 35571387 | Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms. | Ann Transl Med | 2022 | https://conductscience.org/library/papers/35571387 | PubMed |
| 34753495 | BH3-mimetics: recent developments in cancer therapy. | J Exp Clin Cancer Res | 2021 | https://conductscience.org/library/papers/34753495 | PubMed |
| 33883040 | Mitochondrial metabolism as a target for acute myeloid leukemia treatment. | Cancer Metab | 2021 | https://conductscience.org/library/papers/33883040 | PubMed |
| 33799470 | Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/33799470 | PubMed |
| 33335095 | Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. | Signal Transduct Target Ther | 2020 | https://conductscience.org/library/papers/33335095 | PubMed |
| 33256166 | Design, Synthesis and Evaluation of New Bioactive Oxadiazole Derivatives as Anticancer Agents Targeting Bcl-2. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/33256166 | PubMed |
| 33251145 | Targeting Bcl-2 Proteins in Acute Myeloid Leukemia. | Front Oncol | 2020 | https://conductscience.org/library/papers/33251145 | PubMed |
| 33200242 | A decision process for drug discovery in retinoblastoma. | Invest New Drugs | 2021 | https://conductscience.org/library/papers/33200242 | PubMed |
| 32296028 | Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia. | Signal Transduct Target Ther | 2020 | https://conductscience.org/library/papers/32296028 | PubMed |
| 31941776 | Identification and Characterization of Novel Compounds with Broad-Spectrum Antiviral Activity against Influenza A and B Viruses. | J Virol | 2020 | https://conductscience.org/library/papers/31941776 | PubMed |
| 31938458 | Mitochondrial Impairment by Cyanine-Based Small Molecules Induces Apoptosis in Cancer Cells. | ACS Med Chem Lett | 2020 | https://conductscience.org/library/papers/31938458 | PubMed |
| 31869416 | Venetoclax for AML: changing the treatment paradigm. | Blood Adv | 2019 | https://conductscience.org/library/papers/31869416 | PubMed |
| 31717784 | Targeting Apoptotic Pathways in Acute Myeloid Leukaemia. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31717784 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| BCL2 | 596 | PubTator's text mining | https://conductscience.org/library/genes/596 |
Source NCBI Gene
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| OBATOCLAX MESYLATE | CHEMBL2107358 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL2107358 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- References
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19088047
GET https://conductscience.org/api/papers/v1/19088047/cited_by?page=2